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The link between cannabis and psychosis has been debated although there is substantial
epidemiological evidence showing that cannabis increases the risk of psychosis. It
has been hypothesized that schizophrenia patients carrying particular risk genes might
be more sensitive to the psychosis-inducing effects of cannabis than other patients
and healthy test subjects. Here we review the effects of cannabinoids on a mutant
mouse model for the schizophrenia candidate gene neuregulin 1 (Nrg1). The studies
suggest a complex interaction between cannabis and Nrg1: the neuro-behavioral effects
of cannabinoids were different in Nrg1 mutant and control mice and depended on
exposure time, sex, and age of test animals. This research provides the first evidence of
complex cannabis-Nrg1 interactions suggesting Nrg1 as a prime target for future clinical
investigations. Furthermore, it highlights that animal model research can broaden our
understanding of the complex multi-factorial etiology of schizophrenia. Finally, the findings
are important to preventive psychiatry: if the genes that confer genetic vulnerability to
cannabis-induced psychosis were identified patients at-high risk could be forewarned of
the potential dangers of cannabis abuse.
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The two-hit hypothesis of schizophrenia states that a combination
of genetic and environmental risk factors will cause the devel-
opment of schizophrenia (Bayer et al., 1999; Rapoport et al.,
2005; Caspi and Moffitt, 2006). Scores of genetic risk factors
have been suggested for schizophrenia (Allen et al., 2008) and
mouse mutants have been developed for most of those candi-
dates (Desbonnet et al., 2009). Neuregulin 1 (NRG1) is one of
the more promising schizophrenia candidate genes as associations
with schizophrenia have been found in several studies (Stefansson
et al., 2002; Tosato et al., 2005; Munafo et al., 2006). However,
similar to many other schizophrenia susceptibility genes, recent
genome wide associations studies suggest that it is more impor-
tant to consider an interplay of different genetic and environ-
mental risk factors for schizophrenia to understand the etiology
of the disorder (Sanders et al., 2008). Thus, many environmen-
tal factors have been considered as risk factors for schizophrenia
(Van Os et al., 2010) and cannabis use has been the focus of
an ever larger growing list of studies. Cannabis appears to be a
component/cumulative cause for schizophrenia and increases the
overall risk of developing the disorder by 2-fold (Henquet et al.,
2005). Importantly, an increasing number of researchers believe
that this risk might be elevated for cannabis users with a genetic
vulnerability to schizophrenia (Caspi and Moffitt, 2006). Indeed,
a functional polymorphism in the gene for catechol-O-methyl
transferase (COMT) was implicated in conferring vulnerabil-
ity to cannabis-induced psychosis (Caspi et al., 2005; Henquet
et al., 2006). Subsequently, a genetic mouse model for COMT
was treated with the main psychoactive component of cannabis
(9-tetrahydrocannabinol: THC) during adolescence and exhib-
ited a greater behavioral sensitivity to the long-term effects of
THC (O’Tuathaigh et al., 2010) and a genotype-specific response
in dopaminergic and GABAergic pathways as well as in the pro-
tein expression of cannabinoid 1 receptors (CB1) (Behan et al.,
2012). Based onNRG1’s established role in schizophrenia and the
availability of validated mouse mutants for Nrg1 (Duffy et al.,
2008), we investigated over the last decade if Nrg1 represents a
second candidate for gene-cannabis interactions in schizophre-
nia. The mini review will outline how our mouse research has
been instrumental in discovering Nrg1-cannabis interactions rel-
evant to schizophrenia and in deciphering potential mechanisms.
Our studies not only considered THC but also the cannabinoid
cannabidiol (CBD), which is devoid of psychoactive properties
and has been reported to block or reverse effects of THC and have
antipsychotic properties (Arnold et al., 2012).
The protein Nrg1 influences key neurodevelopmental pro-
cesses such as myelination, synaptogenesis, neuronal migration,
and is involved in the expression and activation of N-methyl-D-
aspartic acid (NMDA) receptors (Harrison and Law, 2006; Mei
and Xiong, 2008). Importantly, a number of genetic mouse mod-
els have been developed for the different isoforms of Nrg1 (Duffy
et al., 2008; Mei and Xiong, 2008; Karl et al., 2011). Among
those, the heterozygous transmembrane domain Nrg1 mutant
mouse (Nrg1 HET) has shown compelling face, construct, and
partial predictive validity for schizophrenia research (Stefansson
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et al., 2002; Karl et al., 2007, 2011; Van Den Buuse et al., 2009;
Duffy et al., 2010; Chesworth et al., 2012a,b). Thus, our team
has utilized this model to determine the nature of Nrg1-cannabis
interactions in great detail (for review see Arnold et al., 2012). The
clinical relevance of this research has recently been highlighted
by a genome-wide linkage and single nucleotide polymorphism
association analysis, which discovered NRG1 as a major can-
didate for the development of cannabis dependence in African
Americans (Han et al., 2012). The findings of our earlier mouse
model research will be outlined in the following.
In an initial study we exposed Nrg1 HET mice to acute
doses of THC before testing them in an array of schizophrenia-
relevant behavioral paradigms (Powell and Miyakawa, 2006).
Nrg1 mutant mice exhibited an increased sensitivity to the
locomotor-suppressant and anxiogenic effects of THC compared
to wild type-like littermates (WT). Surprisingly, the mutants
also showed improved sensorimotor gating following THC chal-
lenge as measured by prepulse inhibition of the startle response
(PPI) (Boucher et al., 2007a). Increased PPI is often detected
after treatment with antipsychotic drugs which normalize PPI
deficits of schizophrenia patients (Geyer et al., 2001). Recent
human data suggest that NRG1 may also confer increased behav-
ioral sensitivity to THC [although NRG1 polymorphisms wors-
ened THC-induced information processing dysfunction rather
than improving it (Stadelmann et al., 2010)]. It is possible that
the effects of heterozygous deletion of Nrg1 in mice might be
opposite to that conferred by NRG1 polymorphisms in patients.
Future studies may examine whether mice overexpressing Nrg1
protein display exaggerated THC-induced PPI deficits. Follow-
up experiments revealed that the enhanced behavioral response
of Nrg1 HETs to acute THC was sex-specific as female mutants
showed no enhanced susceptibility to acute THC and actually
developed resistance to aspects of THC-induced social with-
drawal (Long et al., 2010a). It is unclear as to why Nrg1-
cannabinoid interactions are sex-specific. Gender influences the
actions of cannabinoids (McGregor and Arnold, 2007) and inter-
actions between gonadal hormones and neuregulin have been
demonstrated [(Lacroix-Fralish et al., 2006); but also see Taylor
et al., 2011]. Future studies could examine whether Nrg1 expres-
sion regulates the modulatory effects of gonadal hormones on
cannabinoid receptor sensitivity.
The increased behavioral susceptibility ofmaleNrg1HETmice
to THCwas accompanied by elevated neuronal activation as mea-
sured using c-Fos immunohistochemistry (Boucher et al., 2007b).
THC selectively increased c-Fos expression in the ventral part
of the lateral septum (LSV) of Nrg1 mutants. No correspond-
ing effect was observed in control littermates. Interestingly, drugs,
which modulate PPI, whether they are pro-psychotic drugs that
impair PPI, or anti-psychotic drugs that facilitate PPI, all increase
c-Fos expression in the lateral septum (Sumner et al., 2004).
Furthermore, Nrg1 HET mice exhibited a more pronounced
enhancement of c-Fos levels in stress-related brain regions (i.e.,
paraventricular nucleus of hypothalamus and central nucleus of
amygdala). In summary, these animal studies provided the very
first evidence for an interaction between the schizophrenia risk
gene Nrg1 and cannabis and implied that stress and gender may
also influence these interactions.
Chronic cannabis use is more relevant in cannabis-induced
psychosis than acute exposure. Thus, our team continued this
line of research and determined the neuro-behavioral response of
Nrg1 mutants to long-term cannabinoid exposure. Nrg1 mutant
and control mice were treated chronically with the synthetic
CB1 receptor agonist CP 55,940 (Boucher et al., 2011). Nrg1
hypomorphic mice developed tolerance to the hypothermic and
locomotor-suppressant effects of CP 55,940 more rapidly than
WT mice. Interestingly, tolerance development toward the anx-
iogenic effects of the cannabinoid was only observed in control
mice whereas Nrg1 HETs maintained persistent THC-induced
anxiety with repeated CP 55,940 dosing. All mice developed
tolerance to the genotype-specific effects of acute CP 55,940
on PPI (i.e., impairment in WT and facilitation in Nrg1 HET
mice). Mutant mice showed a selective increase in CP 55,940-
induced FosB/FosB expression in the LSV, which is a marker
for long-term neuroadaptive changes. These findings suggest that
Nrg1 is not only involved in the acute neuro-behavioral response
to cannabinoids but also modulates neuroadaptive responses to
long-term cannabinoid challenge. Furthermore, it confirms the
LSV as an important brain region for Nrg1–cannabinoid inter-
actions. This could be related to the fact that the lateral septum
shares reciprocal projections with the hypothalamus and the
amygdala and receives cognitive input from the hippocampus and
the prefrontal cortex (Sheehan et al., 2004). These brain areas
are important in schizophrenia and are characterized by high
expression levels of Nrg1, its main receptor ErbB4 and CB1 (Law
et al., 2004; Kofalvi, 2008; Neddens and Buonanno, 2011). Future
studies should examine inmore detail the role of the LSV inmedi-
ating the neuro-behavioral effects of cannabinoids in Nrg1 HET
mice and define in particular the involvement of CB1 and ErbB4
receptors.
Human research suggests that adolescence is a time of
increased vulnerability to the detrimental effects of cannabis
on the development of psychosis (Caspi et al., 2005). Thus,
our team exposed adolescent WT and Nrg1 HET mice to
chronic THC (Long et al., 2013). Surprisingly, Nrg1 mutants
appeared less susceptible to THC-induced suppression of inves-
tigative social behaviors than control mice. However, adolescent
THC exacerbated the hyperlocomotive phenotype character-
istic for adult Nrg1 mutant mice (Karl et al., 2007; Long
et al., 2013). Nrg1 deficiency also modulated the effects
of adolescent THC on neurotransmitter systems involved
in the pathophysiology of schizophrenia. Radioligand bind-
ing analyses found genotype-specific THC effects on CB1
expression in the substantia nigra: Nrg1 HET mice exhib-
ited reduced CB1 levels drug-free whereas CB1 binding was
decreased in WT and increased in Nrg1 mice post THC chal-
lenge. Lower CB1 expression levels in the substantia nigra
might be responsible for the observed decreased susceptibil-
ity of adolescent Nrg1 mutant mice (whereas binding stud-
ies in adult Nrg1 HETs found increased levels of CB1 in
the same brain region; manuscript currently being submit-
ted). Interestingly, ErbB4 is localized in dopaminergic neurons
in the substantia nigra (Abe et al., 2009). Thus, ErbB4 and
CB1 might interact in the substantia nigra and thereby reg-
ulate the hyper-locomotor phenotype of Nrg1 mutant mice.
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Nrg1 also conferred opposing effects of THC on 5-HT2A recep-
tor expression in the insular cortex and NMDA receptor binding
was selectively increased in the hippocampus and cingulate cortex
of Nrg1 HET mice (Long et al., 2013) (for a better mechanis-
tic understanding of Nrg1-THC interaction on NMDA receptor
expression in the hippocampus see Spencer et al., 2013).
The cannabis sativa plant is a mix of over 60 different
cannabinoids, one being THC, another being CBD, which
blocks, or reverses the effects of THC and other psychotropic
drugs such as methamphetamine (Long et al., 2010b). Varying
levels of THC and CBD in different cannabis strains could
modify the consequences of long-term cannabis consumption
and also shift the nature of gene-cannabis interactions such
as the one reported here for Nrg1. Thus, our team char-
acterized the neuro-behavioral response of Nrg1 HET mice
to acute and chronic CBD (Long et al., 2012) to investi-
gate its potentially therapeutic-like effects in animal models
for schizophrenia. CBD did not alter schizophrenia-relevant
behaviors such as hyperlocomotion or PPI deficits in our Nrg1
HET mouse model (Long et al., 2012). Nevertheless, high dose
CBD selectively increased social interaction of Nrg1 mutant
mice, which are normally characterized by diminished inves-
tigative social behaviors (i.e., social withdrawal) at baseline.
Furthermore, chronic CBD also increased GABAA receptor bind-
ing in the granular retrosplenial cortex of mutant mice sug-
gesting that Nrg1 may not only modulate neuro-behavioral
actions of THC but also of CBD in a task- and brain region-
specific manner. Further research using a variety of CBD doses
thereby considering dose and age-effects will address the issue
of varying or even opposing effects of different cannabinoids
more comprehensively.
In summary, the transmembrane domain Nrg1 mouse model
has enabled the detailed analysis of acute vs. chronic effects
of cannabinoids at different stages of brain development. Nrg1
modulated the behavioral sensitivity of mice to cannabinoids
differentially during adolescence and adulthood providing evi-
dence for a role of Nrg1-cannabis interactions in schizophrenia.
Furthermore, insights into the molecular and neurobiological
mechanisms of Nrg1-cannabinoid interactions (involvement of
CB1, 5-HT2A and NMDA receptors in particular) would not
have been possible without utilizing these mouse mutants. Future
research will extend on our initial findings and address sex speci-
ficity and the opposite effects of CB1 stimulation in adolescence
(Nrg1 mutant less susceptible) and adulthood (Nrg1 mutants
more susceptible) in greater detail. Finally, models of cannabinoid
addiction should be considered given the significant comorbidity
of schizophrenia and drug dependence.
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